Lisa Astor

Findings from the phase 1/2 IPH2201-203 trial support the statement that monalizumab, cetuximab, and durvalumab show promising activity in patients with recurrent squamous cell carcinoma of the head and neck.

Promising results have been reported from the phase 1 study OCTAVE clinical trial.

For patients with advanced synovial sarcoma or myxoid/ round cell liposarcoma, afamitresgene autoleucel is a promising novel therapy.

Major clinical trials are looking to answer substantial questions in the treatment of patients with chronic lymphocytic leukemia, according to Matthew Davids, MD, MMSc.

In an interview with Targeted Oncology, Nicholas J. Vogelzang, MD, discussed how the treatment landscape has changed for renal cell carcinoma and the continuing promise of lenvatinib.

Proactive management of treatment-emergent adverse events, including treatment interruption, may be crucial for patients with renal cell carcinoma receiving lenvatinib in combination with pembrolizumab, according to the CLEAR study investigators.

Survival benefit was shown with the combination of niraparib and rucaparib in patients with chemotherapy-naive metastatic castration-resistant prostate cancer.

An industry-wide evaluation of accelerated oncology drug approvals, where clinical benefit was not verified in subsequent confirmatory trials, called 10 immunotherapy indications into question this year.

Julie R. Brahmer, MD, MSc, FASCO, cochair of the upcoming 19th Annual Winter Lung Cancer Conference, has seen the full development of immunotherapy era in lung cancer from the beginning.

During a conference presentation, A. Oliver Sartor, MD, explained how researchers are building upon the principles of T-cell redirecting agents, such as bispecific T-cell engagers, from other cancer types for the sake of treating patients with prostate cancer.

A significant reduction in the number of patients experiencing grade 3 or 4 toxicity was observed with modified dosing as ipilimumab combine with nivolumab in patients with advanced renal cell carcinoma.

In an interview with Targeted Therapies in Oncology, Nicholas J. Robert, MD, discussed what the results to date of the MYLUNG study mean for patients with non–small cell lung cancer.

The ATLEP study explored the combination of lenvatinib and pembrolizumab in patients with ATC and poorly differentiated thyroid cancer.

Even after more than a decade, the uses of immune checkpoint inhibitors continue to expand across both solid and hematologic malignancies, further adding to the excitement over immuno-oncology.

Mirvetuximab soravtansine is an FRα-targeting antibody-drug conjugate, which in a phase 1/2 study demonstrated significant activity in select patients with ovarian cancer.

Results from the EMPOWER-Cervical 1/ GOG-3016/ENGOT-cx9 trial led the FDA to grant priority review to cemiplimab as treatment of patients with recurrent or metastatic cervical cancer whose disease progressed on or after chemotherapy.

In the phase 3 KEYNOTE-522 trial, pembrolizumab with chemotherapy challenged the standard of care for high-risk, early-stage triple-negative breast cancer with event-free survival improvement.

In an interview prior to the NY Symposium, Perez-Soler, reviewed several areas of development in the lung cancer field that will be addressed during this year’s meeting.

Encouraging results have been reported from the phase 2 Guidance-01 clinical trial.

According to Tycel Jovelle Phillips, MD, the study of venetoclax in combination with the R2 regimen will be expanded to include 50 patients with mantle cell lymphoma without a TP53 mutation.

According to Eliza A. Hawkes, MD, the phase 2 1st FLOR trial showed the positive efficacy of frontline nivolumab in combination with rituximab.

Treatment with larotrectinib in patients with various subtypes of salivary gland tumors led to a high rate early and durable responses.

Responses achieved with immunotherapy preoperatively with could lead to lasting benefit in patients with HOV-associated head and neck squamous cell carcinoma.

Rising interest in SSTR2-targeted radiopharmaceuticals has led to the evaluation of numerous ways to optimize peptide receptor radionuclide therapy in patients with neuroendocrine tumors.

In an interview, Robert J. Motzer, MD, explained how further results of the CLEAR trial, including health-related QOL data, suggest the benefit of pembrolizumab and lenvatinib in patients with advanced RCC.

The FDA has approved the combination of lenvatinib and pembrolizumab for the treatment of patients with advanced endometrial cancer that is not microsatellite instability–high or mismatch repair deficient, who have disease progression following prior systemic treatment and who are not candidates for curative surgery or radiation.

In an interview with Targeted Oncology, Toni K. Choueiri, MD, discussed the results of the KEYNOTE-564 trial as well as the potential effects of these findings.

A biomarker analysis utilized liquid biopsies to find potential prognostic and predictive biomarkers for patients with BRAF V600E–mutant metastatic colorectal cancer treated with BRAF, EGFR, and/or MEK inhibitors.